Protalix BioTherapeutics Crescita futura
Criteri Future verificati 0/6
Si prevede che i ricavi e gli utili di Protalix BioTherapeutics diminuiranno rispettivamente del 6.1% e 69.6% all'anno, mentre si prevede che l'EPS diminuirà del 68.9% all'anno.
Informazioni chiave
-69.6%
Tasso di crescita degli utili
-68.94%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 25.4% |
| Tasso di crescita dei ricavi | -6.1% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 14 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • May 11
PLX: Extended Dosing Approval And 2026 Outlook Will Support Further Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, citing only minor adjustments in discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially alter their overall view of the stock. What's in the News The European Commission approved a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa (Elfabrio) in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every 2 weeks to every 4 weeks (Key Developments).Aggiornamento della narrazione • Apr 26
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts now set Protalix BioTherapeutics' price target at $11.00. The unchanged level reflects only minimal tweaks to inputs such as the discount rate, long term revenue growth, profit margin assumptions and future P/E expectations.Aggiornamento della narrazione • Apr 09
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have maintained their $11.00 price target for Protalix BioTherapeutics, citing relatively stable assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the basis for keeping their outlook unchanged. What's in the News The European Commission approves a 2 mg/kg every four weeks dosing regimen for pegunigalsidase alfa in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every two weeks to every four weeks (Key Developments).Aggiornamento della narrazione • Mar 26
PLX: New Dosing Approval And 2026 Outlook Will Support Undervalued Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, highlighting revised assumptions for revenue growth, profit margins, the discount rate and future P/E as key drivers behind their updated model. What's in the News Protalix BioTherapeutics issued 2026 total revenue guidance of approximately $78.0 million to $83.0 million, which includes a $25.0 million milestone payment from Chiesi tied to regulatory progress for Elfabrio (company guidance).Aggiornamento della narrazione • Mar 09
PLX: Extended Fabry Dosing Will Support Undervalued Long Term Outlook
Analysts have reiterated an $11.00 price target for Protalix BioTherapeutics, citing only slight tweaks to model inputs such as the discount rate, long-term revenue growth, profit margins, and future P/E assumptions rather than any major shift in their overall view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the European Medicines Agency's Committee for Medicinal Product for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy (Key Developments).Aggiornamento della narrazione • Feb 23
PLX: Fabry Dosing Extension Will Support Undervalued Long Term Outlook
Analysts are maintaining their $11.00 price target for Protalix BioTherapeutics while slightly refining core modeling inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions to better align with their updated risk and earnings outlook. What's in the News CHMP of the EMA issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa in adult Fabry disease patients who are stable on enzyme replacement therapy, potentially giving eligible patients a longer interval between infusions (Product related announcement).Aggiornamento della narrazione • Feb 08
PLX: Renal ASO Pipeline And Fabry Dosing Expansion Will Drive Upside
Analysts have maintained their price target for Protalix BioTherapeutics at US$11.00, citing a combination of updated assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple as reasons to keep their existing valuation view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the EMA's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy, aiming to extend time between infusions so patients can focus more on daily life (Key Developments).Aggiornamento della narrazione • Jan 24
PLX: Renal ASO Collaboration Will Drive Next Phase Of Upside Potential
Analysts have maintained their US$11.00 price target for Protalix BioTherapeutics, citing only slight adjustments to their discount rate, long term revenue growth, profit margin assumptions and future P/E outlook, rather than any major shift in their thesis. What's in the News Protalix BioTherapeutics and Secarna Pharmaceuticals entered a collaboration and option agreement to discover antisense oligonucleotide therapies targeting rare renal indications, with Secarna using its OligoCreator platform to design and profile candidates and Protalix selecting the biological targets (Key Developments).Aggiornamento della narrazione • Jan 10
PLX: Renal Collaboration Agreement Will Drive Next Phase Of Upside Potential
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at US$11.00. This reflects only minor adjustments to assumptions around discount rate, revenue growth, profit margins and future P/E that do not materially change their overall view.Aggiornamento della narrazione • Dec 16
PLX: European Label Expansion Review Will Drive Next Phase Of Upside Potential
Analysts have nudged their price target on Protalix BioTherapeutics slightly higher to $11.00, reflecting marginal adjustments to discount rate, long term growth, and profitability assumptions, while maintaining a broadly consistent valuation framework. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics requested re examination of the EMA CHMP negative opinion on adding a once every 4 weeks 2 mg/kg Elfabrio dosing regimen to the currently approved every 2 weeks regimen, seeking broader label flexibility in Europe (Key Developments) Safety data from Elfabrio clinical trials highlighted hypersensitivity reactions in 14 percent of treated patients and anaphylaxis in 3 percent, underscoring the need for careful infusion monitoring and potential dose adjustments (Key Developments) Additional clinical observations included infusion associated reactions in 29 percent of Elfabrio patients and a reported case of membranoproliferative glomerulonephritis, prompting recommendations to monitor renal function and infusion related symptoms (Key Developments) Protalix BioTherapeutics was added to the S&P Global BMI Index, potentially increasing its visibility and accessibility to global institutional investors (Key Developments) Valuation Changes Fair value estimate maintained at $11.00 per share, indicating no change to the analyst target price.Aggiornamento della narrazione • Dec 02
PLX: European Regulatory Review Will Unlock Next Phase Of Upside Potential
Analysts have lowered their price target for Protalix BioTherapeutics from $12.50 to $11.00, citing a slight reduction in expected revenue growth and profit margins. What's in the News Protalix BioTherapeutics and Chiesi Global Rare Diseases have requested a re-examination of the negative opinion by the European Medicines Agency regarding the new dosing regimen for Elfabrio.Aggiornamento della narrazione • Nov 18
PLX: European Review Process Will Drive Next Phase Of Momentum
Analysts have lowered their price target for Protalix BioTherapeutics from $14.00 to $12.50. They cite more conservative expectations regarding revenue growth and profit margins.
Nuova narrazione • May 19
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%. However over the last 3 years revenue has grown on
Nuova narrazione • Apr 29
PRX-115 Trials And Elfabrio Launch Will Open Future Markets
Successful Phase II trials and Chiesi's involvement with Elfabrio could drive growth through new marketable products and increased market adoption.Articolo di analisi • Feb 22
Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon
We feel now is a pretty good time to analyse Protalix BioTherapeutics, Inc.'s ( NYSEMKT:PLX ) business as it appears...Articolo di analisi • Jan 14
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...Articolo di analisi • Dec 10
Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Protalix BioTherapeutics, Inc. ( NYSEMKT:PLX ) can tell us which group is most powerful...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 67 | 1 | N/A | N/A | 1 |
| 12/31/2027 | 68 | 5 | N/A | N/A | 2 |
| 12/31/2026 | 79 | 12 | N/A | N/A | 2 |
| 3/31/2026 | 76 | 15 | 13 | 15 | N/A |
| 12/31/2025 | 53 | -7 | -14 | -12 | N/A |
| 9/30/2025 | 62 | 5 | -12 | -10 | N/A |
| 6/30/2025 | 62 | 6 | -3 | -2 | N/A |
| 3/31/2025 | 60 | 4 | -2 | -1 | N/A |
| 12/31/2024 | 53 | 3 | 7 | 9 | N/A |
| 9/30/2024 | 46 | -10 | 7 | 8 | N/A |
| 6/30/2024 | 38 | -15 | -4 | -3 | N/A |
| 3/31/2024 | 60 | 7 | 4 | 6 | N/A |
| 12/31/2023 | 65 | 8 | -2 | -1 | N/A |
| 9/30/2023 | 64 | 11 | -9 | -8 | N/A |
| 6/30/2023 | 67 | 9 | -11 | -10 | N/A |
| 3/31/2023 | 41 | -16 | -23 | -22 | N/A |
| 12/31/2022 | 48 | -15 | -26 | -25 | N/A |
| 9/30/2022 | 48 | -18 | -28 | -27 | N/A |
| 6/30/2022 | 45 | -18 | -21 | -20 | N/A |
| 3/31/2022 | 43 | -24 | -8 | -6 | N/A |
| 12/31/2021 | 38 | -28 | -12 | -10 | N/A |
| 9/30/2021 | 49 | -21 | -14 | -13 | N/A |
| 6/30/2021 | 48 | -21 | -16 | -14 | N/A |
| 3/31/2021 | 53 | -14 | -30 | -29 | N/A |
| 12/31/2020 | 63 | -7 | -27 | -26 | N/A |
| 9/30/2020 | 61 | -7 | -23 | -22 | N/A |
| 6/30/2020 | 65 | -6 | -23 | -22 | N/A |
| 3/31/2020 | 66 | -9 | -20 | -19 | N/A |
| 12/31/2019 | 55 | -18 | N/A | -19 | N/A |
| 9/30/2019 | 47 | -24 | N/A | -20 | N/A |
| 6/30/2019 | 45 | -26 | N/A | -3 | N/A |
| 3/31/2019 | 38 | -26 | N/A | -6 | N/A |
| 12/31/2018 | 34 | -26 | N/A | -8 | N/A |
| 9/30/2018 | 28 | -34 | N/A | 14 | N/A |
| 6/30/2018 | 23 | -40 | N/A | -10 | N/A |
| 3/31/2018 | 25 | -32 | N/A | -11 | N/A |
| 12/31/2017 | 21 | -83 | N/A | -10 | N/A |
| 9/30/2017 | 19 | -73 | N/A | -35 | N/A |
| 6/30/2017 | 16 | -69 | N/A | -28 | N/A |
| 3/31/2017 | 11 | -80 | N/A | -31 | N/A |
| 12/31/2016 | 9 | -29 | N/A | -32 | N/A |
| 9/30/2016 | 7 | -35 | N/A | -29 | N/A |
| 6/30/2016 | 4 | -34 | N/A | -34 | N/A |
| 3/31/2016 | 3 | -29 | N/A | -27 | N/A |
| 12/31/2015 | 4 | -27 | N/A | -24 | N/A |
| 9/30/2015 | -6 | -31 | N/A | -25 | N/A |
| 6/30/2015 | -4 | -33 | N/A | -26 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che gli utili di PLX diminuiranno nei prossimi 3 anni ( -69.6% all'anno).
Guadagni vs Mercato: Si prevede che gli utili di PLX diminuiranno nei prossimi 3 anni ( -69.6% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di PLX diminuiranno nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che i ricavi di PLX diminuiranno nei prossimi 3 anni ( -6.1% all'anno).
Ricavi ad alta crescita: Si prevede che i ricavi di PLX diminuiranno nei prossimi 3 anni ( -6.1% all'anno).
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di PLX è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 08:19 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Protalix BioTherapeutics, Inc. è coperta da 8 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Peter Welford | Jefferies LLC |